Verified employee & interview reviews

Panacea Biotec Reviews

New Delhi

4.5/ 5

2 reviews

Panacea Biotec Limited is an innovation-driven Indian biotechnology and pharmaceutical company established in 1984 under the name Panacea Drugs Private Limited. Headquartered in New Delhi, India, the company has grown to become one of the largest vaccine manufacturers and biotechnology leaders in the country. It was publicly listed on the Indian stock exchanges, namely the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE), in September 1995. The core operations of Panacea Biotec are broadly divided into two major business segments: Vaccines and Pharmaceutical Formulations & Nutrition. The company engages in the research, development, manufacturing, sales, distribution, and marketing of high-end vaccines, generic drugs, branded formulations, nutraceuticals, and pediatric nutrition products. Its diverse pharmaceutical product portfolio spans several niche therapeutic areas, including oncology, organ transplantation, nephrology, diabetes and cardiovascular management, orthopedics, pain management, and gastrointestinal care. Notably, in 2011, it launched PacliAll, the world's first generic version of protein-bound paclitaxel (Abraxane) for affordable cancer treatment. In the vaccine vertical, Panacea Biotec is globally recognized for its significant contributions to public health and global immunization programs. The company achieved historical milestones by becoming the first to develop and launch a fully liquid Pentavalent vaccine (EasyFive) in 2005 and the world's first fully liquid wP-IPV-based Hexavalent vaccine (EasySix) in 2017. It plays a critical role in partnering with United Nations health agencies for the Global Polio Eradication Initiative, supplying billions of doses of WHO pre-qualified polio vaccines worldwide. Its current pipeline includes promising candidates such as DengiALL, a tetravalent dengue vaccine, and NucoVac 11, a pneumococcal conjugate vaccine. The company operates advanced, vertically integrated research and development centers and state-of-the-art manufacturing facilities. Its key production plants are located in Lalru, Punjab, and Baddi, Himachal Pradesh. These facilities comply with current Good Manufacturing Practices (cGMP) and are accredited by major global regulatory authorities, including the US Food and Drug Administration (USFDA) and the World Health Organization (WHO). Its R&D division employs hundreds of highly skilled scientists focused on novel drug delivery systems, new chemical entities, and recombinant vaccines, holding hundreds of granted patents globally. Managed by a strong promoter group under the leadership of Managing Director Dr. Rajesh Jain, Panacea Biotec focuses on making innovative healthcare products affordable and accessible. The company maintains a strong international footprint, exporting its formulations and vaccines to approximately 50 countries across Latin America, Asia, Africa, the Middle East, and CIS nations. With a dedicated workforce of nearly 1,900 employees, it continues to focus on complex, high-barrier healthcare solutions.